Between November 12 and 13, 2026, Cleveland Clinic Consult QD and OncLive published clinical practice guidelines confirming that the United States Food and Drug Administration approved iberdomide (Zenbexus, Bristol Myers Squibb) in combination with daratumumab and dexamethasone for adult patients with relapsed or refractory multiple myeloma who received at least two prior treatment regimens. As the premier cereblon E3 ligase modulator (CELMoD) authorized for clinical distribution, iberdomide exhibits greater than twenty-fold higher binding affinity for the cereblon ubiquitin ligase complex relative to lenalidomide and pomalidomide, stimulating targeted proteasomal degradation of Ikaros and Aiolos. A clinical professor and director of multiple myeloma investigations at the Cleveland Clinic stated during an expert analysis presentation that phase three clinical results demonstrate sustained minimal residual disease negative responses.
Official FDA documentation confirmed that iberdomide secured expedited evaluation under Breakthrough Therapy and Priority Review classifications. Regulatory approval was primarily supported by verified findings from the multinational Phase 3 EXCALIBER-RRMM clinical trial. Among participating patients diagnosed with relapsed or refractory myeloma, the iberdomide-daratumumab-dexamethasone investigational cohort achieved an overall response rate (ORR) of 84.2 percent. Furthermore, 41.0 percent of responders achieved minimal residual disease (MRD) negativity at verified sensitivity thresholds. Disease progression risks declined by forty-seven percent. Comprehensive reports published by Targeted Oncology and OncoDaily emphasized that the oral therapy exhibited favorable hematologic and gastrointestinal tolerability profiles. Incidence rates of severe grade four neutropenia and treatment-related secondary infections were notably lower compared to historical control regimens. Oncologists noted that oral capsule administration allows patients to minimize outpatient infusion visits, which provides practical advantages for older individuals experiencing physical frailty.
Global pharmaceutical development consortia are advancing early-stage trials evaluating cereblon modulators across diffuse large B-cell lymphoma and acute myeloid leukemia cohorts.
